Market Overview:
The global lipid-lowering agent market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of obesity and diabetes, increasing awareness about the benefits of lipid-lowering agents, and technological advancements in the field of lipid-lowering agents. Based on type, the global lipid-lowering agent market is segmented into niacin, acipimox, fibrates, and others. Niacin is expected to dominate the market during the forecast period owing to its high efficacy in lowering bad cholesterol levels (LDL) and triglycerides levels. Fibrates are also expected to witness significant growth during the forecast period due to their ability to lower LDL cholesterol levels as well as blood sugar levels. Based on application, hospitals are estimated account for a major share of revenue generated by sales of lipid-lowering agents during 2018–2030 followed by clinics.
Product Definition:
A lipid-lowering agent is a drug that reduces levels of lipids in the blood, including cholesterol and triglycerides. Lipid-lowering agents are used to prevent and treat cardiovascular disease.
Niaci:
Niaci, also known as nicotinic acid, is a vitamin-like organic compound that is produced in the human body. It has been used for centuries in food and feedstock for animals. In humans, it functions as an inhibitor of niacinamide biosynthesis through the liver and kidneys.
Acipimox:
Acutimox is a lipoprotein-lowering agent that works by reducing the amount of fat, cholesterol and triglycerides in the body. It reduces levels of high density lipoprotein (HDL) which is usually known as good cholesterol and increases levels of low-density lipoprotein (LDL) which is usually known as bad or lipid-lowering agent.
Application Insights:
The others segment held the largest share of over 50.0% in 2017. The application of lipid-lowering agents other than hospitals and clinics is expected to witness a CAGR of XX% from 2018 to 2030 owing to growing awareness about cardiovascular diseases and increasing incidences of heart attacks among both, old as well as young people globally.
Hospitals were the largest revenue generating centers for all types of lipids lowering drugs in 2017 due largely to factors such as large patient base with similar disease conditions across the globe, availability of high quality healthcare services at low costs and prevalence rate for cardiac disorders being higher in hospital settings than that outside hospitals which attracts more patients towards these facilities resulting in larger revenue generation for this segment compared to others globally.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable government initiatives, and high awareness levels regarding the availability of these products are some factors responsible for its large share. For instance, in May 2018, Merck & Co., Inc. announced to donate USD X million over a period of five years to help establish the “2020: A New Vision†initiative by the U.S Department of Health and Human Services (HHS). This initiative is aimed at accelerating new discoveries that can reduce cardiovascular disease burden in America by 2020%.
Asia Pacific is expected to be one of fastest growing regions due to rising healthcare expenditure levels coupled with increasing prevalence rates for various diseases such as diabetes and cardiac disorders among others which can be reduced using lipid-lowering agents such as niacin or acipimox therapy leading to an increase demand for these drugs over a forecast period from 2018 To 2030 timeframe.
Growth Factors:
- Increasing prevalence of obesity and metabolic syndrome
- Rising geriatric population
- Growing demand for preventive cardiology treatments
- Technological advancements in lipid-lowering therapies
- Increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Lipid-lowering Agent Market Research Report
By Type
Niaci, Acipimox, Fibrates, Others
By Application
Hospitals, Clinics, Others
By Companies
Pfizer, Merck, Teva, Amgen, Abbott, AstraZeneca, Novartis, SUN Pharma, Torrent Pharmaceuticals, GlaxoSmithKline, Pfizer, JX Pharmaceuticals, Aurobindo Pharma, Abbvie, Cerenis Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
169
Number of Tables & Figures
119
Customization Available
Yes, the report can be customized as per your need.
Global Lipid-lowering Agent Market Report Segments:
The global Lipid-lowering Agent market is segmented on the basis of:
Types
Niaci, Acipimox, Fibrates, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Merck
- Teva
- Amgen
- Abbott
- AstraZeneca
- Novartis
- SUN Pharma
- Torrent Pharmaceuticals
- GlaxoSmithKline
- Pfizer
- JX Pharmaceuticals
- Aurobindo Pharma
- Abbvie
- Cerenis Therapeutics
Highlights of The Lipid-lowering Agent Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Niaci
- Acipimox
- Fibrates
- Others
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lipid-lowering Agent Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A lipid-lowering agent is a medication that helps lower the levels of harmful cholesterol and triglycerides in the blood.
Some of the key players operating in the lipid-lowering agent market are Pfizer, Merck, Teva, Amgen, Abbott, AstraZeneca, Novartis, SUN Pharma, Torrent Pharmaceuticals, GlaxoSmithKline, Pfizer, JX Pharmaceuticals, Aurobindo Pharma, Abbvie, Cerenis Therapeutics.
The lipid-lowering agent market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Lipid-lowering Agent Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Lipid-lowering Agent Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Lipid-lowering Agent Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Lipid-lowering Agent Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Lipid-lowering Agent Market Size & Forecast, 2018-2028
4.5.1 Lipid-lowering Agent Market Size and Y-o-Y Growth
4.5.2 Lipid-lowering Agent Market Absolute $ Opportunity
Chapter 5 Global Lipid-lowering Agent Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Lipid-lowering Agent Market Size Forecast by Type
5.2.1 Niaci
5.2.2 Acipimox
5.2.3 Fibrates
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Lipid-lowering Agent Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Lipid-lowering Agent Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Lipid-lowering Agent Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Lipid-lowering Agent Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Lipid-lowering Agent Analysis and Forecast
9.1 Introduction
9.2 North America Lipid-lowering Agent Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Lipid-lowering Agent Market Size Forecast by Type
9.6.1 Niaci
9.6.2 Acipimox
9.6.3 Fibrates
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Lipid-lowering Agent Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Lipid-lowering Agent Analysis and Forecast
10.1 Introduction
10.2 Europe Lipid-lowering Agent Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Lipid-lowering Agent Market Size Forecast by Type
10.6.1 Niaci
10.6.2 Acipimox
10.6.3 Fibrates
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Lipid-lowering Agent Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Lipid-lowering Agent Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Lipid-lowering Agent Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Lipid-lowering Agent Market Size Forecast by Type
11.6.1 Niaci
11.6.2 Acipimox
11.6.3 Fibrates
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Lipid-lowering Agent Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Lipid-lowering Agent Analysis and Forecast
12.1 Introduction
12.2 Latin America Lipid-lowering Agent Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Lipid-lowering Agent Market Size Forecast by Type
12.6.1 Niaci
12.6.2 Acipimox
12.6.3 Fibrates
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Lipid-lowering Agent Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Lipid-lowering Agent Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Lipid-lowering Agent Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Lipid-lowering Agent Market Size Forecast by Type
13.6.1 Niaci
13.6.2 Acipimox
13.6.3 Fibrates
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Lipid-lowering Agent Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Lipid-lowering Agent Market: Competitive Dashboard
14.2 Global Lipid-lowering Agent Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Merck
14.3.3 Teva
14.3.4 Amgen
14.3.5 Abbott
14.3.6 AstraZeneca
14.3.7 Novartis
14.3.8 SUN Pharma
14.3.9 Torrent Pharmaceuticals
14.3.10 GlaxoSmithKline
14.3.11 Pfizer
14.3.12 JX Pharmaceuticals
14.3.13 Aurobindo Pharma
14.3.14 Abbvie
14.3.15 Cerenis Therapeutics
